Twist-2 Controls Myeloid Lineage Development and Function

Andrew B. Sharabi1, Melissa Aldrich1, Drazen Sosic2, Eric N. Olson2, Alan D. Friedman3, Sung-Hyung Lee4, Si-Yi Chen1,4*

1 Department of Immunology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, United States of America, 2 Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 3 Division of Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland, United States of America, 4 Department of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America

Basic helix-loop-helix (bHLH) transcription factors play critical roles in lymphoid and erythroid development; however, little is known about their role in myeloid lineage development. In this study, we identify the bHLH transcription factor Twist-2 as a key negative regulator of myeloid lineage development, as manifested by marked increases in mature myeloid populations of macrophages, neutrophils, and basophils in Twist-2-deficient mice. Mechanistic studies demonstrate that Twist-2 inhibits the proliferation as well as differentiation of granulocyte macrophage progenitors (GMP) by interacting with and inhibiting the transcription factors Runx1 and C/EBPα. Moreover, Twist-2 was found to have a contrasting effect on cytokine production: inhibiting the production of proinflammatory cytokines such as interleukin-12 (IL-12) and interferon-γ (IFNγ) while promoting the regulatory cytokine IL-10 by myeloid cells. The data from further analyses suggest that Twist-2 activates the transcription factor c-Maf, leading to IL-10 expression. In addition, Twist-2 was found to be essential for endotoxin tolerance. Thus, this study reveals the critical role of Twist-2 in regulating the development of myeloid lineages, as well as the function and inflammatory responses of mature myeloid cells.

Introduction

Hematopoietic cell development and function must be tightly regulated to maintain homeostasis. Cell fates are established by master transcription factors that orchestrate determination and differentiation. Disruption of this regulation can lead to lethal consequences for the host in the form of myelodysplasias or leukemia. Development of the terminally differentiated myeloid lineages follows a hierarchy starting with the hematopoietic stem cell (HSC) [1–3], which gives rise to a series of rapidly dividing committed progenitors [4,5], namely the common myeloid progenitor (CMP) and granulocyte macrophage progenitor (GMP). The identification of specific surface markers has allowed for prospective isolation of these populations and has facilitated investigation of the transcriptional regulation that occurs during myelopoiesis [6–8]. Transcription factors, including PU.1 and C/EBPα, play critical roles in development of myeloid lineages because in the absence of these factors, specific populations fail to develop or are severely altered. PU.1 plays a broad role in determination of both myeloid and lymphoid lineages, as mice deficient in PU.1 fail to develop B cells, T cells, granulocytes, or macrophages [9]. C/EBPα is necessary for proper granulocyte colony-stimulating factor receptor (G-CSFR) promoter transactivation as well as additional downstream activities, and is hence required for formation of the GMP and myeloid lineage commitment [10–14]. Although many transcription factors have been identified that play critical roles in promoting myeloid lineage development, factors that naturally function to inhibit or negatively regulate myeloid lineage development are largely unknown and require further characterization. These inhibitory factors may play equally important roles in regulating hematopoiesis by preventing excessive myeloid lineage development or myeloproliferative disease. Furthermore, aberrant expression of inhibitory factors, as exemplified by the Runx1-ETO fusion protein, which functions as a dominant-negative regulator of the transcription factor Runx1 and an inhibitor of the C/EBPα promoter [15,16], may play a direct role in leukemogenesis by blocking normal differentiation and creating an enlarged pool of progenitors that are prone to malignant transformation.

Importantly, many basic helix-loop-helix (bHLH) transcription factors, including the E2A family, stem cell leukemia factor (SCL/Tal1), Lyl-1, and the helix-loop-helix (HLH) Id family, are known to be important regulators of hematopoiesis [17–21]. bHLH factors form heterodimers or homodimers that can bind E-box DNA consensus sites comprised of the sequence 5’-CANNTG-3’. SCL is a bHLH factor that is required for definitive hematopoiesis [18,19]. SCL knockout (KO) mice are embryonic lethal due to a failure in primitive lineage development or myeloproliferative disease. Furthermore, aberrant expression of inhibitory factors, as exemplified by the Runx1-ETO fusion protein, which functions as a dominant-negative regulator of the transcription factor Runx1 and an inhibitor of the C/EBPα promoter [15,16], may play a direct role in leukemogenesis by blocking normal differentiation and creating an enlarged pool of progenitors that are prone to malignant transformation.

* To whom correspondence should be addressed. E-mail: siyichen@usc.edu
**Author Summary**

Hematopoiesis is coordinated by transcription factors that regulate proliferation, differentiation, and cell fate determinations. Myelopoiesis refers to the development of all white blood cells, excluding lymphocytes (B and T cells); however, the molecular regulation of this developmental process is still incompletely understood. In this study using mice that lack expression of Twist-2, we establish a novel role for this basic helix-loop-helix transcription factor as regulator of myeloid progenitors and fully differentiated myeloid cells. Specifically, Twist-2 acts to inhibit proliferation as well as differentiation of progenitors that give rise to macrophages, neutrophils, and basophils by inhibiting the important transcription factors Runx1 and C/EBPα. In mature myeloid cells, Twist-2 negatively regulates the production of proinflammatory cytokines while positively promoting the production of regulatory cytokine IL-10 by these cells. These findings provide significant insight into regulation of myeloid lineage development and function.

**Results**

**Preferential Expression of Twist-2 in Myeloid Progenitors**

In order to identify bHLH factors that regulate myeloid development, we first used Gene Expression Omnibus (GEO) microarray dataset GSE3722 to analyze the expression of a panel of candidate genes, including known myeloid transcription factors and bHLH factors in CMP and GMP (Figure S1). Subsequent semiquantitative reverse transcription PCR (RT-PCR) analysis of sorted hematopoietic progenitors from wild-type (WT) C57Bl/6 mice (Figure S1) showed that Twist-2 was preferentially expressed in Lin IL7R Sca-1 c-KitCD34 FcyRIII/IIIA+ CMP, but not or weakly expressed in the Lin IL7R Sca-1 c-Kit hematopoietic progenitor compartment containing HSC or Lin IL7R Sca-1 c-Kit common lymphoid progenitors (CLP) (Figure 1A). In contrast to the preferential expression of Twist-2, Twist-1 was expressed in all types of progenitors we examined (Figure 1A).

**Quantitative RT-PCR assays further confirmed the preferential and constitutive expression of Twist-2 in CMP and GMP populations (Figure 1B).**

**Twist-2 KO Mice Have Significant Systemic Increases in Multiple Myeloid Lineages**

The Twist family of bHLH transcription factors, including Twist-1 and Twist-2, are key regulators of mesodermal differentiation [33] and also play a role in the epithelial to mesenchymal transition involved in cancer metastasis [34]. Twist-2 is known to inhibit the terminal differentiation of a variety of mesodermally derived cell types including myocytes, osteoblasts, and adipocytes [29–32]. Although many of the known HLH factors are direct dimerization partners with Twist-2, there are no reports, to our knowledge, investigating the role of Twist-2 in hematopoiesis.

To investigate the possible role of Twist-2 in hematopoiesis, we enumerated mature myeloid cells and other types of immune cells from lymphoid organs in age- and sex-matched Twist-2 knockout (KO) (+/−) mice and wild-type (+/+ ) littermates. Twist-2 KO mice develop a severe inflammatory syndrome, and the majority of mice die within 2 wk after birth [35]. This phenotype is associated with elevated serum levels of the cytokines interleukin-1 (IL-1) and tumor necrosis factor-α (TNFα) due to derepression of necrosis factor-α (NF-κb) activity [35,36]. Upon analyzing Twist-2 KO mice, we observed similar percentages of T cells and B cells in the spleens as compared to WT littermates (Figure 1C). However, we found a significant increase in CD11b+Gr-1+ myeloid cells in the spleens of Twist-2 KO mice (Figure 1C, lower panel). In order to determine whether this myeloid population was systemically increased, we analyzed the liver, blood, and bone marrow (BM), and found increases in CD11b+Gr-1+ populations in each of these tissues and organs of Twist-2 KO mice (Figure 1D). Using the specific macrophage marker F4/80, we identified this increased population to include both CD11b+Gr-1+ F4/80+ macrophages and CD11b+Gr-1+ F4/80− neutrophils (Figure 1E). In addition, we observed an increase in CD11c+ myeloid DCs in spleens of Twist-2 KO mice, with equal contributions to two major DC subtypes, namely CD11c+CD11b+CD4+ and CD11c−CD11b−CD8+ DCs (Figure 1F).

Multiple different cell types of the myeloid lineage stain positive with CD11b and Gr-1 antibodies, and so in order to distinguish these myeloid cell subpopulations, we performed automated complete blood counts (CBC) with differentials on peripheral blood obtained from a series of eight Twist-2 KO mice and WT littermates. Twist-2 KO mice have increased percentages and absolute cell counts of multiple myeloid lineages, including a 2–3-fold increase in macrophages and neutrophils as well as an 18-fold increase in absolute basophil count (Table 1). There was no apparent change in absolute lymphocyte, red blood cell, or platelet counts in peripheral blood, suggesting that other lineages, including megakaryocyte and erythroid lineages, were not significantly affected. Histology of whole bone mounts demonstrated a largely...
Figure 1. Twist-2–Deficient Mice Have Significant Increases in Multiple Myeloid Cells in Multiple Organs

(A and B) Semiquantitative (A) and quantitative (B) RT-PCR of sorted hematopoietic progenitor populations showing constitutive expression of Twist-2 in GMP and CMP populations. Data are normalized to 18s rRNA internal controls and representative of two independent experiments. Error bars indicate the standard deviation (SD).

(C) Splenocytes of Twist-2 KO and WT littermates were analyzed by flow cytometry. Results are representative of eight independent pairs of mice analyzed. CD11c^+ and CD8^+ T cells (upper panel), IgM^+ and IgD^+ B cells (middle panel), and Gr-1^+ granulocytes and macrophages (lower panel) are shown.

(D) Flow cytometry showing expansion of CD11b^Gr-1^- myeloid cells in peripheral blood (upper panel), liver (middle panel), and BM (lower panel) of Twist-2 KO mice representative of six independent experiments.

(E) Flow cytometric analysis of splenocytes showing the expansion of Gr-1^+CD11b^+ F4/80^+ macrophages (upper panel) and F4/80^+CD11b^+Gr-1^- neutrophils (lower panel) in Twist-2 KO mice representative of three independent experiments.

(F) Absolute cell counts of CD11c^+ cells and two major DC subtypes, CD11c^+CD11b^-CD4^+ and CD11c^-CD11b^-CD8^- cells, are both increased in Twist-2 KO spleen. Error bars indicate SD.

(G) Images of whole bone mounts stained with H&E (left panels). BM touch preps stained with Wright-Giemsa (right panels) show higher numbers of mature myeloid cells in the Twist-2 KO BM.

(H) Images of peripheral blood smears with Wright-Giemsa stain showing hypersegmented neutrophils and enlarged monocytoid cells in Twist-2 KO mice. Images are representative of four independent sets of peripheral blood smears. The arrow indicates the hypersegmented nuclei of the neutrophils. doi:10.1371/journal.pbio.0060316.g001

Intact architecture of the trabecular bone in Twist-2 KO mice (Figure 1G, left panel). Histological analysis of Twist-2 KO BM revealed increases in myeloid cells in multiple stages of maturation (Figure 1G, right panel and arrows), which is consistent with the CD11b^Gr-1^- phenotype of the expanded myeloid populations (Figure 1C–F). Interestingly, we observed that hypersegmented neutrophils and atypical monocytes were present in peripheral blood smears of Twist-2 KO mice (Figure 1H), which are pathologic findings that can be observed in the setting of myelodysplastic and myeloproliferative diseases [37]. Furthermore, the dramatic increase in basophils is suggestive of a myeloproliferative disease because basophilia is mainly observed in the setting of myeloproliferative disease and cases of chronic myeloid leukemia [38,39].

Increases in Myeloid Cells Due to an Intrinsic Feature of Hematopoietic Progenitors Deficient in Twist-2

To mechanistically investigate the increase in myeloid cells observed in Twist-2 KO mice, we first tested whether a decrease in apoptosis or cell turnover of these myeloid cells in the periphery results in their accumulation. Splenocytes from Twist-2 KO and WT littermates were cultured in complete media and stimulated with proapoptotic cytokines. Cells were then analyzed by flow cytometry with staining for Annexin-V and propidium iodide (PI). Twist-2 KO CD11b^Gr-1^- cells did not show any increased resistance to cell death. In fact, there was a slightly increased susceptibility to apoptosis as indicated by the increased percentage of Annexin-V^+PI^+ Twist-2 KO cells (Figure 2A). In addition, we did not observe any apparent difference in the percentage of CD11c^+Annexin-V^+PI^+ late apoptotic or necrotic DCs derived from Twist-2 KO and WT BMs (Figure 2B), thus it is unlikely that the increased populations of myeloid cells we observed in Twist-2 KO mice are due to decreased cell turnover or resistance to apoptosis in these populations. Another possibility is that a change in cell trafficking may result in relative increases of these myeloid cells in specific organs or tissues at the expense of others. However, this possibility was largely excluded due to the observed increases in multiple tissues and organs of Twist-2 KO mice, including the BM. The possibility of increased myeloid cells as a result of infection was also unlikely, due to the lack of evidence of infection in these mice and to their housing in a pathogen-free barrier facility. Next, we examined the possibility that altered or dysregulated hematopoiesis in Twist-2 KO mice results in increased production or myeloproliferation.

Table 1. Complete Blood Counts with Differentials on Peripheral Blood

| Peripheral Blood Counts | Genotype       | Twist-2^+/+ (Mean ± SD) | Twist-2^-/- (Mean ± SD) |
|-------------------------|----------------|-------------------------|-------------------------|
| Neutrophils, %          | 6.43 ± 0.85   | 13.55 ± 2.74            |
| Lymphocytes, %          | 84.08 ± 2.42  | 68.93 ± 2.95            |
| Monocytes, %            | 3.80 ± 1.46   | 6.48 ± 3.05             |
| Basophils, %            | 4.45 ± 0.50   | 6.75 ± 2.71             |
| Neutrophils, cells/µl  | 220 ± 38      | 518 ± 99                |
| Lymphocytes, cells/µl   | 3030 ± 419    | 2965 ± 775              |
| Monocytes, cells/µl     | 124 ± 63      | 305 ± 179               |
| Basophils, cells/µl     | 160 ± 14      | 263 ± 99                |
| RBC, X 10^6/µl          | 5.37 ± 0.45   | 5.64 ± 0.61             |
| HGB, g/dl               | 9.4 ± 0.37    | 9.58 ± 0.73             |
| HCT, %                  | 27.9 ± 0.84   | 27.88 ± 1.99            |
| PLT, X 10^3/µl          | 661 ± 319     | 562 ± 214               |

The table shows specific increases in multiple myeloid lineages, including macrophages, neutrophils, and basophils in Twist-2 KO mice (n = 8 per group); 2–3-fold increases in macrophages and neutrophils and an 18-fold increase in absolute cell count of basophils were observed in the peripheral blood of Twist-2 KO mice. HCT, Hematocrit; HGB, hemoglobin; PLT, platelets; RBC, red blood cells; SD, standard deviation.

doi:10.1371/journal.pbio.0060316.t001

Increases in Myeloid Lineage Progenitors in Twist-2–Deficient Mice

To investigate the intrinsic mechanism for the observed increases in myeloid cells in Twist-2 KO mice, we used flow cytometric analysis to examine the HSC and progenitor populations. We observed a subtle decrease in the Lin^-c-Kit^-Sca-1^- HSC compartment and percentage of Lin IL7R*Sca-1^-c-Kit^CD34^+FCyRII/III^+ CMP in Twist-2 KO BM (Figure 2C and 2D). In contrast, we found a significant expansion of the Lin IL7R*Sca-1^-c-Kit^CD34^+FCyRII/III^+ high GMP population in the BM and spleens of Twist-2 KO mice (Figure 2D and 2G).

Downstream progenitors and immediate myeloid precursors could also contribute to myeloproliferation in Twist-2 KO mice. Recently, there has been significant progress in identifying specific surface markers of these precursor populations and delineating their hierarchical program of differentiation [7,40–42]. Mouse DC precursors in the BM have been defined as being Lin^-c-Kit^+Flt3^-MCSFR^+ [43,44],...
and mouse DC precursors in the peripheral blood have been also immunophenotypically defined as being CD11c<sup>+</sup>IL7R<sup>+</sup> [41]. We stained for these cells in Twist-2 KO mice and WT littermates, and found significant increases in Lin<sup>+</sup>c-Kit<sup>+</sup>Flt3<sup>+</sup>MCSFR<sup>+</sup> and CD11c<sup>+</sup>IA-<sup>E</sup>- DC precursors in the BM and peripheral blood of Twist-2 KO mice, respectively (Figure 2E and 2F). Recently, a basophil mast cell progenitor (BMCP) has been identified in the mouse spleen that is characterized as being Lin<sup>+</sup>c-Kit<sup>+</sup>FcyR<sup>+</sup>Beta<sup>7<sup>+</sup> [42]. The addition of the Beta<sup>7</sup> marker appears to fractionate BMCP from Lin<sup>+</sup>c-Kit<sup>+</sup>FcyR<sup>+</sup>Beta<sup>7</sup>- GMP. Importantly, we observed an increase in BMCP in the spleens of Twist-2 KO mice (Figure 2G). Taken together, these data indicate that Twist-2 plays a role in negatively regulating differentiation and development of myeloid lineages in vivo.

Twist-2–Deficient Hematopoietic Progenitors Are Skewed toward Myeloid Differentiation In Vitro and In Vivo

To further investigate whether Twist-2 functions as a suppressor of myeloid cell lineage differentiation, we first used methylcellulose colony formation assays to analyze the relative ability of the BM from WT and Twist-2 KO littermates to differentiate into hematopoietic colonies in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) in vitro. Figure 3A shows that BM from Twist-2 KO mice produced a significantly increased number of total colonies, suggesting a hypersensitivity to GM-CSF–induced differentiation or proliferation (Figure 3A). Next, we analyzed the types of colonies produced upon hematopoietic differentiation in MethoCult GF M3434 (StemCell Technologies), which supports differentiation of multiple hematopoietic lineages in vitro. Under these conditions, we observed a significant increase in the relative percentage of myeloid colonies (colony-forming unit granulocyte macrophage [CFU-GM], CFU macrophage [CFU-M], and CFU granulocyte [CFU-G]) as identified by their characteristic morphologies (Figure 3B). Interestingly, when analyzing the resulting colonies by flow cytometry, we observed an increase in Lin<sup>-</sup>Sca-1<sup>-</sup>c-Kit<sup>+</sup> cells, suggesting an increased maintenance or proliferation of myeloid progenitors (unpublished data). In addition, we observed increased percentages of both CFU-GM and CFU-M differentiated in vitro from mouse embryonic stem cells in which Twist-2 was specifically silenced by short interfering RNA (siRNA) (unpublished data).

To examine whether Twist-2 regulates myeloid skewing at the single-cell level, we sorted the upstream CMPs, which have both myeloid and erythroid potential, into individual wells containing MethoCult GF M3434 and cultured the cells for 10 d. Resultant colonies were scored for their respective type (BFU-E/CFU-E, mixed GEMM, and CFU-GM(CFU-M)). In agreement with in vitro differentiation assays using whole BM cells (Figure 3A and 3B), Twist-2 KO CMP cells were clearly skewed towards differentiating into myeloid colonies (Figure 3C). Next, we performed competitive and non-competitive BM transplantation assays to assess the intrinsic effects of Twist-2 during hematopoiesis. Lethally irradiated syngeneic WT mice receiving Twist-2 KO BM had a significantly expanded myeloid compartment in the BM at 4 wk (Figure 3D). Absolute cell counts of multiple myeloid lineages in the peripheral blood were increased at 8 wk after transplantation as compared to control mice receiving WT BM (Figure 3E). Since it is possible that the downstream effects of Twist-2 on cytokine production could alter hematopoiesis, we performed competitive BM transplantation assays using congenic markers to assess the independent effects of Twist-2 on hematopoiesis in vivo. We admixed WT CD45.1 BM 1:1 with either WT CD45.2 or Twist-2 KO CD45.2 BM, and transplanted the cells into lethally irradiated CD45.1 congenic mice. Upon analyzing the mice at 4 wk, we observed a relatively equal contribution to the CD11b<sup>+</sup>Gr-1<sup>+</sup> myeloid compartment in mice that received the WT:WT BM (Figure 3F). However, in mice that received the WT:KO admixed BM, an enhanced fraction of the CD11b<sup>+</sup>Gr-1<sup>+</sup> myeloid cells was derived from the Twist-2 KO BM, indicating that the Twist-2 KO cells have a competitive advantage over WT cells, given the same in vivo microenvironment (Figure 3F, right panel). Collectively, these data demonstrate the skewed myeloid lineage differentiation of Twist-2–deficient progenitor cells in vitro and in vivo, and indicate that Twist-2 is likely an intrinsic inhibitor of myeloid differentiation.

Hyperproliferation of Twist-2–Deficient GMP Cells

To examine whether Twist-2 also plays a role in regulating the proliferation of myeloid progenitor cells, we first sorted single cells of Lin<sup>-</sup>IL7R<sup>-</sup>Sca-1<sup>-</sup>c-Kit<sup>+</sup>CD34<sup>+</sup>FcyRIII/IIb<sup>hi</sup> GMP from the BM of Twist-2 KO and WT littermates into individual wells of 96-well plates and analyzed their differentiation and proliferation in MethoCult GF M3434 (StemCell Technologies). It was apparent that the individual colony sizes derived from the Twist-2 KO GMP cells were significantly larger than those from WT GMP cells (Figure 3G). Individual colonies from Twist-2 GMP cells also had increased cell density (unpublished data). In order to quantify this observation, we used an image analysis software package to measure the average size of the colonies. Figure 3H shows that the average size of Twist-2 KO GMP-derived colonies was more than 3.5 times larger than that of WT GMP-derived colonies, indicating the enhanced proliferation and differ-
Twist-2 in Myeloid Lineage

A

B

C

E

F

D

G

H

I

Twist-2 in Myeloid Lineage

A

B

C

E

F

D

G

H

I
Twist-2 Suppresses the Production of Proinflammatory Cytokines and Chemokines, Including IL-12

By using quantitative RT-PCR analysis, we found that Twist-2 mRNA were expressed in myeloid DCs at low levels, but were rapidly up-regulated in response to stimulation with a Toll-like receptor-4 (TLR4) ligand (LPS) (Figure 5A), which prompted us to investigate whether Twist-2 plays a role in regulation of the function of differentiated myeloid cells. We analyzed the production of inflammatory cytokines by CD11c⁺ splenic myeloid DCs and BM-derived DCs (BMDC) from Twist-2 KO mice using bead-based cytokine arrays and ELISA assays. Figure 5B and 5C show that Twist-2 KO DCs produced elevated levels of the proinflammatory cytokines IL-12, IFNγ, IL-1, TNFα, and IL-6 upon LPS stimulation as compared to WT DC. Production of chemokines, including MCP-1 and MIP-1α, was also significantly increased from Twist-2 KO DCs (Figure 5B). Yet, the surface expression of costimulatory molecules on Twist-2 KO DCs was not significantly altered compared to that on WT DCs (Figure S3). We also set out to examine whether Twist-2 could be involved in mediating endotoxin tolerance, a protection system to prevent harmfully excessive inflammation responses to LPS. DCs from Twist-2 KO and WT littermates were stimulated with LPS for 24 h, then washed and restimulated with LPS to assay for endotoxin tolerance. Figure 5C shows that Twist-2 KO DCs continue to produce high levels of proinflammatory cytokines such as IL-6, TNFα, and IL-12 in response to repeated LPS stimulation. In contrast, WT DCs significantly lost the ability to produce...
Figure 4. Twist-2 Inhibits the Transcriptional Activity of Runx1 and C/EBPα.

(A) Immunoblot assay of COS7 cells transiently transfected with indicated plasmids. After 48 h, cells were lysed in NTN buffer containing 0.5% NP-40 and 0.5% Triton X-100. Cell lysates were analyzed by immunoblotting (IB) with anti-FLAG or anti-myc antibodies (upper two panels). Cell lysates were also immunoprecipitated (IP) with anti-myc antibody followed by immunoblotting with anti-FLAG antibody (lower panel).

(B and C) COS7 cells were transiently transfected with a Runx1-responsive luciferase reporter (CBF4_Luc, 1 μg), or Runx1 expression plasmid (Runx1, 1 μg), or indicated amounts of Twist expression constructs. pcDNA3.1 blank vector control was cotransfected so that each well received the same total amount of DNA (4 μg). After 24 h, luciferase activity in cell extracts was quantified via luciferase assay (B). Runx1 responsive luciferase reporter cotransfected with empty vector control or Twist-2 expression vector only (C). Data are presented as mean ± SD, and the results are representative of three independent experiments.

(D and E) Luciferase reporter assays were performed on cells transfected with indicated plasmids (1 μg each). Twist-2 vector cotransfection inhibited the activity of a C/EBPα-dependent luciferase reporter in COS7 cells ([D] left panel), but not a PU.1-dependent luciferase reporter ([D] right panel). A CREB-responsive luciferase reporter from the PEPCK promoter cotransfected with empty vector control or Twist-2 expression vector only ([E]). Data are presented as mean ± SD, and the results are representative of three independent experiments.

doi:10.1371/journal.pbio.0060316.g004
Figure 5. Twist-2 Differentially Regulates the Production of Pro- and Anti-Inflammatory Cytokines by Myeloid Cells

(A) Induced expression of Twist-2 mRNA in CD11c+ BM DCs after 4 h of stimulation of LPS (100 ng/ml), as demonstrated by quantitative RT-PCR. Data are normalized to 18S rRNA internal controls, with samples loaded in triplicate from repeated experiments.

(B) Representative cytokine production by Twist-2 KO and WT DCs after 24 h of stimulation with 100 ng/ml LPS. Data, presented as mean ± SD, are representative of three independent experiments.

(C) Endotoxin tolerance assays. DCs were pretreated with 100 ng/ml LPS for 24 h, washed twice in complete medium, and then allowed to rest for 2 h,
proinflammatory cytokines in response to repeated LPS stimulation. Thus, a biological function of Twist-2 is to maintain endotoxin tolerance to prevent acute excessive inflammatory responses by myeloid cells.

In order to differentiate between the effects of Twist-2 on myeloid cell development versus those on homeostasis in mature progeny, we performed rescue experiments by reexpressing Twist-2 in differentiated KO cells to investigate the reversibility of the proinflammatory cytokine phenotype. BMDCs were generated from WT and Twist-2 KO mice and transfected with a Twist-2 expression vector or empty vector control by Nucleofection (Figure S4). Cells were rested overnight, stimulated with LPS for 24 h, and supernatant was analyzed by ELISA assays. We observed a significant reduction in the production of inflammatory cytokines and chemokines upon rescue of Twist-2 expression in Twist-2 KO BMDC (Figure 5D). We also noticed that overexpression of Twist-2 also suppressed the production of these cytokines and chemokines by WT BMDCs. Thus, these data suggest that the role of Twist-2 in regulating cytokine and chemokine production in differentiated myeloid cells is distinct from its effects on myeloid differentiation.

**Twist-2 Promotes the Production of Anti-Inflammatory Cytokine IL-10**

We unexpectedly found that Twist-2 KO myeloid DCs produced significantly lower levels of the critical anti-inflammatory cytokine IL-10 when compared to WT myeloid DCs (Figure 5B). Further analyses showed that the production of Th2 polarizing IL-4 by Twist-2 KO DCs was also considerably lower (Figure 5B). Twist was previously found to act either as an activator or a repressor of somatic muscle development in *Drosophila* depending upon its dimerization partner [45,48]. To investigate the molecular mechanism by which Twist-2 promotes IL-10 production, we first used an IL-10 promoter-driven luciferase reporter assay. It was observed that Twist-2 did not enhance the IL-10 promoter-derived transcription (unpublished data). Several recent studies have demonstrated that the transcription factor c-Maf is important for the transcription of IL-10 as well as IL-4 [49,50]. Accordingly, we measured the expression of the transcription factor c-Maf in Twist-2 KO and WT DCs. Figure 6A shows that the mRNA levels of c-Maf in Twist-2 KO DCs were significantly lower than those in WT DCs, especially after the stimulation with a TLR agonist, suggesting that Twist-2 is an activator of c-Maf transcription. To further investigate this possibility, we performed chromatin immunoprecipitation (ChIP) assays using 3T3 fibroblasts which express high levels of Twist-2. We found that primers (pair 1) specific for a highly conserved E-box–containing region of the c-Maf promoter (Figure 6B) generated bands from both the RNA-positive control and anti-Twist-2 antibody pulldown, but not control antibody pulldown (Figure 6C). In contrast, negative control primers (pair 2) specific for a region of genomic DNA approx 20 kb upstream of the c-Maf gene (Figure 6B and 6C) did not show significant pulldown with any antibody. Densitometry quantified a 24-fold enrichment of specific c-Maf promoter DNA pulldown using Twist-2 antibody as compared to control immunoglobulin G (IgG), suggesting that Twist-2 directly binds the c-Maf promoter (Figure 6D). To further investigate whether Twist-2 is an activator of c-Maf, we cotransfected the expression vectors containing 1.6- or 1.3-kb 5′-flanking region of the *c-maf* gene fused to the luciferase gene [51] with the Twist-2 expression vector or control blank vector into COS cells. Figure 6E shows that Twist-2 activated both *c-maf* promoter constructs. Thus, these data suggest that Twist-2 promotes the production of IL-10 and IL-4, possibly via the activation of c-Maf transcription.

**Discussion**

In this study, we found that Twist-2 is constitutively expressed in myeloid progenitors and plays a critical role in the suppression of myeloid lineage differentiation into macrophages, neutrophils, and basophils. We further found that Twist-2 not only inhibits the myeloid differentiation of GMP, but also inhibits the proliferation of GMP population. Moreover, we demonstrated that Twist-2 has inhibitory effects on the activity of Runx1 and C/EBPα, which may contribute to the suppression of GMP differentiation and proliferation by Twist-2. Thus, this study reveals the critical, unrecognized role for Twist-2 in negative regulation of GMP proliferation and myeloid lineage differentiation. In addition, we found that Twist-2 regulates the function and inflammatory responses of differentiated myeloid cells by promoting the production of the important regulatory cytokine IL-10 and inhibiting the production of proinflammatory cytokines and chemokines.

Twist-1 and Twist-2 are highly conserved; however, deficiency in Twist-1 and Twist-2 results in different phenotypes: Twist-1 KO mice are embryonic lethal due to a failure in neural tube closure, whereas Twist-2 KO mice develop a severe inflammatory syndrome and die within 2 wk of birth [35,52]. Twist-1 heterozygous null mice have skeletal and bone defects that mimic patients with Saethre-Chotzen syndrome caused by mutations in human Twist-1 [46,53–55]. Twist-2 is a known developmental regulator of mesodermally derived cell types [29–32]. In this study, we found that Twist-2, but not Twist-1, is selectively expressed in GMP and CMP, and it suppresses GMP differentiation as well as proliferation.

The Runx family comprised of Runx1, Runx2, and Runx3 are master transcription factors that regulate cell-cycle progression and differentiation. Runx1 is essential for definitive hematopoiesis [56–58], and plays an important role in adult hematopoiesis in both lymphoid and myeloid progenitor compartments [59,60]. Runx1 regulates myelopoiesis by coordinating expression of GM-CSF, M-CSFR, myeloperoxidase, and neutrophil elastase [61–64]. In this study, we found that Twist-2 inhibited the function of the transcription factor Runx1, which may contribute to the myeloproliferative disease observed in Twist-2 KO mice. In addition, Runx1 is a target of one of the most common
translocations (t(8;21)) in acute myeloid leukemia (AML), which
generates the dominant-negative Runx1-ETO fusion protein
to suppress Runx1 activity, leading to the blockade of myeloid
lineage differentiation and an accumulated progenitor pool
that is prone to malignant transformation [60]. In addition, C/EBPα,
a member of the basic region–leucine zipper CCAAT/enhancer-binding protein (C/EBP) transcription factors, is a
potent inhibitor of cell cycle in myeloid cells and other types
of cells due to binding E2F1. Thus, the suppression of GMP
proliferation by Twist-2 may be due to the inhibition of C/EBPα.
However, it is possible that Twist-2 interacts with and
suppresses additional unrecognized factors. Taken together,
our results suggest that Twist-2 suppresses the differentiation
and proliferation of GMP, possibly via the inhibition of the
transcription factors Runx1 and C/EBPα.

An interesting unexpected finding of this study is that
Twist-2 promotes the production of the important regulatory
cytokine IL-10 [65] by differentiated myeloid cells. The
etiology of the lethal inflammatory phenotype of Twist-2
KO mice is distinct, but not well understood [35]. The
enhanced production of proinflammatory cytokines in
combination with the reduced production of anti-inflamma-
tory cytokine IL-10 may contribute to the lethal inflammation
of Twist-2 KO mice [35,36]. In addition, hyperproliferation
of myeloid progenitors and the expanded population of differ-
entiated inflammatory myeloid cells found in Twist-2 KO
mice may perpetuate the lethal inflammation. Different from
the constitutive expression of Twist-2 in GMP, the expression
of Twist-2 in differentiated myeloid cells such as DCs and
macrophages was induced in response to TLR agonists such
as LPS. Twist-2 was previously shown to directly bind the p65
subunit of NF-κB and inhibit the transactivation and
production of inflammatory cytokines such as TNFα, IL-1,
and IL-6 [35]. In this study, we found that the production of
Th1-polarizing cytokines such as IL-12 and IFNγ was also
critically regulated by Twist-2. This is in agreement with a
recent study describing a role for Twist-1 in regulating Th1
cytokines in T-cells [66]. We further demonstrated that the
mechanism for the suppression of IL-12 production by Twist-2
involves inhibition of NF-κB activity, not via the direct
binding of Twist-2 to E-boxes in the IL-12 promoter
(unpublished data). It was previously reported that C/EBPα
and NF-κB p50 or p65 directly interact and cooperate to
activate proinflammatory genes [67]. Our finding of the
inhibition of C/EBPα by Twist-2 raises an interesting
possibility that the critical regulation of proinflammatory

Figure 6. Twist-2 Is an Activator of c-Maf and Essential for Endotoxin Tolerance

(A) Quantitative RT-PCR of relative c-Maf mRNA levels in Twist-2 KO and WT BMDCs with or without LPS stimulation from three independent
experiments. (B–D) Schematic diagram of c-Maf promoter region and locations of primer pairs: (1) spanning a highly conserved region of the c-Maf promoter
containing multiple E-box consensus sites, and (2) spanning a “promoter desert” region of genomic DNA approximately 20 kb upstream of the c-Maf
promoter used for the ChIP assay (B). ChIP of 3T3 fibroblasts using an anti–Twist-2 antibody probing for c-Maf promoter DNA pulldown or an anti-RNA
Poly (positive) or IgG (negative) controls (C) from one representative of two repeated experiments. Primer sequences available upon request.

Densitometric analysis of relative ChIP PCR band intensity (upper panel) was normalized to input (D).

(E) Activation of c-Maf promoter by Twist-2. COS7 cells were cotransfected with cMaf promoter-driven luciferase vectors containing approximately 1.6
kb (cMaf_R1.6) or 1.3 kb (cMaf_R1.3) of the rat cMaf promoter region [51] and Twist-2 or empty vector (pcDNA3.1) for 32 h before analyzing for
luciferase activity. Double asterisks (**) indicate p < 0.01
doi:10.1371/journal.pbio.0060316.g006

PLoS Biology | www.plosbiology.org December 2008 | Volume 6 | Issue 12 | e316
cystokines by Twist-2 may be a result of the inhibition of both NF-κB and C/EBPβ proteins by Twist-2. Moreover, Twist-2 was found to have a critical role in maintaining endotoxin tolerance. Thus, Twist-2, in addition to its critical role in regulation of myeloid lineage differentiation and the proliferation of myeloid progenitors, uniquely regulates pro-inflammatory responses to prevent excessive inflammation by inhibiting proinflammatory cytokines and promoting anti-inflammatory cytokine production.

IL-10 is a potent anti-inflammatory cytokine and plays a critical role in maintaining homeostasis of the immune system and protecting the host from excessive inflammation [65]. Despite its biological importance, the regulation of IL-10 gene expression remains poorly defined. In this study, we found that Twist-2 promotes the expression of IL-10, not via direct activation of the IL-10 promoter, but possibly through the activation of c-Maf transcription. We demonstrated that Twist-2 is likely a transcriptional activator of c-Maf. BHLH transcription factors have been known to function as activators or repressors, depending on the partners or cofactors [45,48]. c-Maf is the cellular counterpart of oncogenic v-Maf in the acute transforming avian retrovirus AS42 that induces musculoaponeurotic fibrosarcoma (Maf) [68]. c-Maf is a member of the family of basic region–leucine zipper domain transcription factors, and the target genes of c-Maf in various cell lineages include the insulin gene in islet β cells and IL-4 and IL-10 in T cells and myeloid cells [49,69,70]. Collectively, the data suggest a possible positive role of Twist-2 in the Maf transcription and subsequent IL-10 production in myeloid cells. Further studies are warranted to investigate the role of Twist-2 in regulation of innate and adaptive immunity.

Materials and Methods

Mice. Twist-2 heterozygous null mice were crossed to generate Twist-2 KO mice [35]. In all experiments, WT littermates were used for controls. Mice were maintained in a pathogen-free barrier facility, and all experiments were performed in accordance with the Baylor College of Medicine Institutional Animal Care and Use committee.

Immunostaining and cell sorting. Single-cell suspensions were prepared from indicated solid organs of mice 10–12 d old. Red blood cells were lysed with Trias-ammonium chloride lysis buffer. Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood by gradient centrifugation. Fc receptor block was performed using anti-mouse CD16/CD32 Fc block antibody (BD Pharmingen), except in cases when the Fc receptor was used to identify CMP or GMP. Cells were stained with combinations of fluorescein isothiocyanate, phycoerythrin, allophycocyanin, peridinin chlorophyll protein, or phycoerythrin-Cy7-conjugated CD4, CD8, IgM, IgD, CD11b, Gr-1, Annexin-V, lineage cocktail (CD4, CD8, Ter-119, CD11b, Gr-1, and B220), IL-7R, Sca1, c-Kit anti-mouse antibodies (BD), or APC-conjugated F4/80 (Caltag Labs), or biotinylated FcγRII/II followed by staining with streptavidin-PerCP Ab (BD). Cells were analyzed and sorted on a FACSaria (BD) as described [71]. FACs data were analyzed using FlowJo Software (TreeStar).

Hematopoietic colony assays. Single-cell suspensions of BM after ammonium chloride lysis were plated into 60-mm dishes (2 × 10⁴ cells/dish) with MethoCult M3001 (containing only GM-CSF) or GF M3434 as indicated (StemCell Technologies). Cells were cultured at 37 °C, 5% CO₂, and hematopoietic colonies were counted and scored after 12 d of incubation, or as indicated.

CBC analysis and histology. Peripheral blood from Twist-2 KO mice and WT littermates 10–12 d old was collected via retro-orbital bleed into Microvets coated with EDTA (SARSTEDT). Automated complete blood count with differential was performed using an Advia 120 (Bayer Diagnostics, SIEMENS). Peripheral blood smears were generated and imaged (BX51 Olympus Microscope). For whole bone mounts, femurs were fixed and processed for paraffin embedding and stained with hematoxylin and eosin (H&E). For BM histology, femurs were incised lengthwise, and BM was gently touched to the surface of a glass slide, followed by Wright-Giemsa staining and pathological analysis.

ELISA. BM-derived DCs were generated as previously described [71,72]. Primary CD11c⁺ splenic DCs were purified from single-cell suspensions of splenocytes using CD11c⁺ magnetic-activated columns (Miltenyi Biotec). DCs were cultured onto 24-well plates and stimulated with 100 ng/ml LPS for 24 h. For some assays, WT and KO BMDCs were transfected with Twist-2 expression vectors using the AMAXA Mouse Dendritic cell Nucleofector kits [73]. Briefly, 2.5 × 10⁶ BMDC per condition were electroporated with either 2 μg of pcDNA3.1 empty vector control or 2 μg of Twist-2 expression construct and plated into 48-well plates in RPMI supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine. Cells were rested overnight and then stimulated with 100 ng/ml LPS for 24 h. Supernatants were harvested and analyzed by ELISA.

 Luciferase reporter assay. COS7 cells (0.6 × 10⁶ cells/well) or 293T cells were seeded into 6-well plates and cultured for 24 h in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM l-glutamine. Cells were washed with serum-free (SF) DMEM and cotransfected with indicated plasmid expression vectors using Geneporter (Gene Therapy Systems). The Runx1, C/EBPβ, and PU.1 expression constructs and respective luciferase reporter constructs have been described [74,75]. An empty vector control was added so that each well received the same total amount of DNA. After 4 h, an equal volume of DMEM supplemented with 20% FCS was added to the wells. Cells were cultured for an additional 24 h, and luciferase activity of cell extracts was measured on a luminometer normalized to total protein concentrations using the Dual-Luciferase Reporter Assay System (Promega).

EMSA. Sorted GMP (2 × 10⁵ cells) from Twist-2 KO mice or WT littermates were lysed in 25 μl of NTN lysis buffer containing phosphatase inhibitor cocktail 1 and 2 (SIGMA) and Complete Mini Inhibite Inhibitor Cocktail (Roche). Lysates were incubated on ice for 45 min and cleared by centrifugation at 14,000 × g for 10 min. Clear lysates were reacted for 20 min at room temperature (RT) with biotinylated oligo duplexes (Operon) containing the wild-type or mutated RUNX1 consensus binding site from the M-CSF promoter: WT sense: 5'-AGCATTACCTCGTGTGCTGCTCCCT-3', WT antisense: 5'-TGGAAAGGCAACGCACAGAGGT-3'; mutant sense: 5'-AGCAATCTTGTACCGTGCCTGGCCCT-3'; mutant antisense: 5'-TGGAAAGGCAACGCACAGAGGT-3'. Nonbiotinylated oligos were used as additional controls. Binding reactions and EMSA were set up and performed using the LightShift Chemiluminescent EMSA Kit (Pierce) and Chemiluminescent Nucleic Acid Detection Module (Pierce) according to the manufacturers' protocols. Briefly, reacted samples were immediately loaded and electrophoresed on 6% DNA retardation gels (Invitrogen) in 0.5X TBE and transferred to BrightStar-Plus positively charged nylon membrane (Ambion). DNA was crosslinked at 120 mJ/cm² using a GS Gene Linker UV Chamber (Bio-Rad). Membranes were blocked and biotin-labeled DNA was detected and visualized using streptavidin-HRP followed by ECL reagent (Pierce).

RT-PCR. For real-time quantitative RT-PCR, total RNA was isolated from indicated cell type using the RNeasy kit (Qiagen). First-strand cDNA was synthesized from 200 ng of total RNA for hematopoietic stem or progenitor cells or from 4 μg of total RNA for mature cells using the Superscript II First-Strand Synthesis System (Invitrogen). Real-time quantitative RT-PCR was set up using TaqMan Universal PCR Master Mix (Applied Biosystems) and analyzed on an ABI Prism 7900HT Real-Time PCR System (Applied Biosystems). TaqMan gene expression assays for indicated genes were ordered from Applied Biosystems. All data were normalized to 18S rRNA internal controls [72,76]. For semiquantitative RT-PCR 25 ng of first-strand cDNA was amplified using Twist-1- or Twist-2-specific primers (sequences available upon request) for 40 cycles using HPRT primers as controls.

ChIP and immunoprecipitation. 3T3 fibroblasts were grown in 10-cm plates until semi-confluent. Cells were fixed in 1% paraformaldehyde, and ChIP was performed using the EZ ChIP Kit according to the manufacturer's instructions. Brittle, from approximately 20 × 10⁶ cells was sonicated using a Bath sonicator (Bioruptor). Precleared lysates were incubated with Anti-RNA Polymerase II (Clone CTD4H8), normal mouse IgG, or anti-Twist-2 antibodies (H-81 sc-15393) overnight at 4 °C. Immunocomplexes were collected by incubation with 1 μg of indicated primers. Densitometry was performed to quantify relative band intensity as normalized to input. Primer sequences would be provided upon request. For immunoprecipitation, COST7
cells in 10-cm plates were transduced with indicated plasmids and cultured for 48 h. Cells were lysed in 500 μl of NTN NP-40 lysis buffer containing protease inhibitor cocktail (Roche) and lysate was homogenized by passing through a 21G needle. Lysate was incubated with antibodies overnight at 4 °C followed by addition of Protein G-Sepharose beads (Zymed) and incubation for 2 h. Beads were washed four times, suspended in 70 μl of SDS loading buffer, and then incubated at 95 °C for 8 min. Samples were analyzed by western blotting with either anti-FLAG or anti-Myc primary antibodies (Sigma) and secondary antibody conjugates (Sigma).

**Figure S2.** Electrophoretic Moiblity Shift Assay of Sorted GMPs
Whole-cell lysates of sorted Lin^−/C^−/C^−/F^+^/F^+^/CD34^+^/Fc^cR^II/III^+^ GMPs (2 × 10^6^) from WT and Twist-2 KO mice were reacted with biotinylated oligos containing the endogenous Runx1 consensus binding site (Runx1 probe) or mutated Runx1 consensus binding site (mutant Runx1 Probe), and EMSA was performed. Arrow indicates specific Runx1 band retardation. An asterisk (*) indicates nonspecific band. Densitometry was performed on WT and KO bands indicated with arrow and was normalized to background in each lane. Experiment was repeated twice with similar results.

**References**

1. Sphnagle GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. Science 241: 58–62.

2. Osawa M, Hanada K, Hamada H, Nakauchi H (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 275: 242–245.

3. Iwasaki H, Akashi K (2007) Myeloid lineage commitment from the hematopoietic stem cell. Annu Rev Cell Dev Biol 21: 55–71.

4. Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193–197.

5. Traver D, Miyamoto T, Christensen J, Iwashaki-Arai J, Akashi K, et al. (2001) Fetal liver myelopoiesis occurs through distinct, prospectively isolatable progenitor subsets. Blood 98: 627–635.

6. Friedman AD (2007) Transcriptional control of granulocyte and monocyte development. Oncogene 26: 6816–6828.

7. Iwasaki H, Akashi K (2007) Myeloid lineage commitment from the hematopoietic stem cell. Immunity 26: 726–740.

8. Rosenbauer F, Tenen DG (2007) Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 7: 105–117.

9. Scott EW, Simon MC, Anastasi J, Singh H (1994) Requirement of Twist-2 Expression in CMP and GMP
References

10. Wang D, D’Costa J, Civin CI, Friedman AD (2006) C/EBPalpha directs granulocyte colony-stimulating factor (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DCs. Blood 107: 4568–4574.

11. Wang QF, Friedman AD (2002) CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 99: 2776–2785.

12. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG (1996) PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88: 1254–1267.

13. Zheng DE, Zhang QH, He, H, Herbst-Hoover RJ, Darlington GJ, et al. (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94: 569–574.

14. Elbashir SM, Goldfarb AN (2006) Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of norm marrow maturation. Cancer Lett.

15. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, et al. (2001) AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in (8;21) myeloid lineage. Blood 108: 1223–1229.

16. Zhang P, Iwashaki-Arai J, Iwashaki H, Froyon ML, Dayaram T, et al. (2004) Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 21: 853–863.

17. Murre C (2005) Helix-loop-helix proteins and lymphocyte development. Nat Immunol 6: 1079–1086.

18. Robb L, Lyons I, Li R, Hartley L, Kontgen F, et al. (1995) Absence of yolk sac hematopoiesis from mice with a targeted disruption of the slc1 gene. Proc Natl Acad Sci U S A 92: 7970–7974.

19. Shvidsana RA, Mayer EL, Orkin SH (1995) Absence of blood formation in mice lacking the T-cell leukemia oncprotein tal-1/SLCL. Nature 375: 452–455.

20. Capron C, Lecluse Y, Kaushik A, Fland R, Lacout C, et al. (2006) The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood 107: 4678–4686.

21. Cathleen I, Cooper PEN (1998) Differential expression of Id genes in multipotent myeloid progenitor cells. Id-1 is induced by early- and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation. J Cell Biochem 71: 277–285.

22. Hall MA, Curtiss DJ, Metcaf D, Elefanty AG, Soures K, et al. (2003) The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S. Proc Natl Acad Sci U S A 100: 992–997.

23. Zhan Q, Soriano P, Weintraub H (1994) The helix-loop-helix gene E2A is required for B cell formation. Cell 79: 875–884.

24. Baim G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, et al. (1994) E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 79: 885–892.

25. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, et al. (1999) Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397: 762–766.

26. Kawka T, Fujimoto S, Kawamoto H, Katsura Y, Yokota Y (2001) Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc Natl Acad Sci U S A 98: 5184–5189.

27. Spetsis H, Conwenberg F, Bakker AQ, Weijer V, Uittenbogaart CH (2000) Id2 and Id5 inhibit development of CD34+ stem cells into preadult hematopoiesis (pre-DC2) but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2. J Exp Med 192: 1775–1784.

28. Dahl R, Walsh JC, Labin C, Lierb S, Pher SR, et al. (2005) Regulation of macrophage and neutrophil cell fate by the PU.1/CEBPa ratio and granulocyte colony-stimulating factor. Nat Immunol 4: 1029–1036.

29. Lee YS, Lee HH, Park J, Yoo EJ, Glackin CA, et al. (2003) Twist2, a novel E2A zinc finger protein, represses the transcriptional activity of ADD1/SREBP1c interacting protein, represses the transcription of SREBP1c and Gene Therapy for helpful suggestions and assistance.

**Acknowledgments**

We thank Lisa Rollins and other members of the Chen lab for technical assistance and valuable suggestions. We also thank Dr. Gerard Kirszenfatt for transferring the Twist-2 KO mice. Dr. Masaharu Sakai at Hokkaido University, Japan, for providing c-maf-Luc vectors, and Dr. Margaret Goodell and other colleagues at the Center for Cell and Gene Therapy for helpful suggestions and assistance.

**Author contributions.** ABS and SYC conceived and designed the experiments, ABS, MA, and SHL performed the experiments, ABS, D’s, and SYC analyzed the data, DS, ENO, and ADF contributed reagents/materials/analysis tools. ABS and SYC wrote the paper.

**Funding.** This work was supported by grants from the National Institutes of Health (R01CA90427, R01CA116677, and R01AI68472), training grants (T32 AI07495–11, T32 DK064717–03), and the Leukemia and Lymphoma Society Specialized Center of Research (SCOR).

**Competing interests.** The authors have declared that no competing interests exist.
null heterozygous mouse phenotype resemble those of human Saethre-
Chotzen syndrome. Hum Mol Genet 7: 945–957.

35. el Ghoulzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, et al. (1997) Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 17: 42–46.

36. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 312–320.

37. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, et al. (1996) Disruption of the Cbfalpha2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 93: 3444–3449.

38. North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, et al. (2002) Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 16: 661–672.

39. Grouwey JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, et al. (2005) Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloprolif- erative phenotype. Blood 106: 494–504.

40. Ichikawa M, Asai T, Saito T, Sato S, Yamazaki I, et al. (2004) AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10: 299–304.

41. Otto F, Lubbert M, Stock M (2005) Upstream and downstream targets of RUNX proteins. J Cell Biochem 89: 9–18.

42. Lutterbach B, Hiebert SW (2000) Role of the transcription factor AML1 in acute leukemia and hematopoietic differentiation. Gene 245: 225–235.

43. Cripps RM, Black BL, Zhao B, Lien C-L, Schulz RA, et al. (1998) The variable expressivity and incomplete penetrance of the twist-heterozygous mouse phenotype. Proc Natl Acad Sci U S A 95: 7221–7226.

44. Carver EA, Oram KF, Gridley T (2002) Craniosynostosis in Twist-null heterozygous mouse phenotype resemble those of human Saethre-
Chotzen syndrome. Hum Mol Genet 7: 945–957.

45. el Ghoulzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, et al. (1997) Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 17: 42–46.

46. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 312–320.

47. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, et al. (1996) Disruption of the Cbfalpha2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 93: 3444–3449.

48. North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, et al. (2002) Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 16: 661–672.

49. Grouwey JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, et al. (2005) Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloprolif- erative phenotype. Blood 106: 494–504.

50. Ichikawa M, Asai T, Saito T, Sato S, Yamazaki I, et al. (2004) AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10: 299–304.

51. Otto F, Lubbert M, Stock M (2005) Upstream and downstream targets of RUNX proteins. J Cell Biochem 89: 9–18.